Marketing-authorisation holder
Novartis Pharmaceuticals Corporation
216 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
216 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 216
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACYLANID0.1mg · Tablet | Acetyldigitoxin | United States | Not marketed | |
| ADAKVEO100mg/10ml · Injectable | Crizanlizumab | United States | Marketed | 2019 |
| AFINITOR10mg | 2.5mg | 5mg | 7.5mg · Tablet | Everolimus | United States | Marketed | 2009 |
| AFINITOR DISPERZ2mg | 3mg | 5mg · Tablet, for suspension | Everolimus | United States | Marketed | 2012 |
| ALOMIDE0.1% base · Solution/drops | Lodoxamide | United States | Not marketed | 1993 |
| AMTURNIDE150mg base; 5mg base; 12.5mg | 300mg base; 10mg base; 12.5mg | 300mg base; 10mg base; 25mg | 300mg base; 5mg base; 12.5mg | 300mg base; 5mg base; 25mg · Tablet | Aliskiren hemifumarate, Amlodipine, Hydrochlorothiazide | United States | Not marketed | 2010 |
| ANTRENYL5MG · Tablet | Oxyphenonium | United States | Not marketed | |
| ANTURANE100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Sulfinpyrazone | United States | Not marketed | 1959 |
| ANTURANE200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Sulfinpyrazone | United States | Not marketed | 1959 |
| APRESAZIDE100mg; 50mg | 25mg; 25mg | 50mg; 50mg · Capsule | Hydralazine, Hydrochlorothiazide | United States | Not marketed | 1976 |
| APRESOLINE20MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Hydralazine | United States | Not marketed | 1953 |
| APRESOLINE100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 50MG **Federal Register · Tablet | Hydralazine | United States | Not marketed | 1953 |
| APRESOLINE-ESIDRIX25mg; 15mg · Tablet | Hydralazine, Hydrochlorothiazide | United States | Not marketed | |
| ARCAPTA NEOHALER75mcg base · Powder | Indacaterol | United States | Not marketed | 2011 |
| AREDIA30MG/VIAL | 30MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 60MG/VIAL | 90MG/VIAL · Injectable | Pamidronic acid | United States | Marketed | 1991 |
| ARZERRA100mg/5ml · Injectable | Ofatumumab | United States | Marketed | 2009 |
| ASBRON150mg base · Tablet | Theophylline glycinate | United States | Not marketed | |
| BEOVU6mg/0.05ml · Injectable | Brolucizumab | United States | Marketed | 2019 |
| Beovu6mg/0.05ml · Injection | Brolucizumab | United States | Marketed | 2022 |
| BETOPTIC S0.25% base · Suspension/drops | Betaxolol | United States | Marketed | 1989 |
| BRETHAIRE0.2mg/inh · Aerosol, metered | Terbutaline | United States | Not marketed | |
| BUTAZOLIDIN100mg · Capsule | Phenylbutazone | United States | Not marketed | 1997 |
| BUTAZOLIDIN100mg · Tablet | Phenylbutazone | United States | Not marketed | 1997 |
| CAFERGOT100mg; 1mg · Tablet | Caffeine, Ergotamine | United States | Not marketed | 1948 |
| CAFERGOT100MG; 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Suppository | Caffeine, Ergotamine | United States | Not marketed | 1953 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 216 | 213 | 3 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.